Recent Advances in Pathologic Research and Targeted Therapies of Thymoma
DOI:
https://doi.org/10.30683/1929-2279.2019.08.02Keywords:
Thymic epithelial tumors, gene therapy, targeted therapy, molecular pathology.Abstract
Thymoma is a rare tumor that was reclassified by the World Health Organization in 2015. Recent studies have made advances in molecular targeted therapies, such as c-KIT, EGFR, IGF-1R, PTEN, HDAC, VEGF and PD-L1. Additionally, new molecular markers such as CTV/CTS, GTF2I, Pax8 and DSG-3 have been used in the differential diagnosis of thymoma. This article reviews molecular pathogenesis of thymoma, application of molecular pathology in the differential diagnosis of thymoma and recent progress in targeted therapies for thymoma.
References
Wu Jianguo, Cao Yong, Chen Bien,Wen Qiongna. 2013. Correlation between VEGF expression and PI3K/AKT pathway in Thymoma. Chinese And Foreign Medical Research, 11(17): 5-7.
Travis William D, Brambilla Elisabeth, Burke Allen P, Marx Alexander, Nicholson Andrew G. 2015. Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart. J Thorac Oncol, 10, 1240-1242. https://doi.org/10.1097/JTO.0000000000000663 DOI: https://doi.org/10.1097/JTO.0000000000000663
Saito Motonobu, Fujiwara Yutaka, Asao Tetsuhiko, Honda Takayuki, Shimada Yoko, Kanai Yae, Tsuta Koji, Kono Koji, Watanabe Shunichi, Ohe Yuichiro, Kohno Takashi. 2017. The genomic and epigenomic landscape in thymic carcinoma. Carcinogenesis, 38, 1084-1091. https://doi.org/10.1093/carcin/bgx094 DOI: https://doi.org/10.1093/carcin/bgx094
Shi Feng. 2015.Expression of c-myc and PTEN genes in Thymoma[J]. Med Innov China, 12(32): 43-46.
Masunaga Atsuko, Omatsu Mutsuko, Kunimura Toshiaki, Uematsu Shugo, Kamio Yoshito, Kitami Akihiko, Miyagi Yohei, Hiroshima Kenzo, Suzuki Takashi, 2017. PTEN Expression of and its pseudogene, and promoter methylation of in non-tumourous thymus and thymic tumours. J. Clin. Pathol, 70, 690-696. https://doi.org/10.1136/jclinpath-2016-204220 DOI: https://doi.org/10.1136/jclinpath-2016-204220
Wang Hai. 2016.Expression of Wnt4 and FoxN1 in Thymoma and its correlation with malignant degree of Thymoma. Tianjin Medical University.
Meng Fanqing, Nie Ling. 2015. Interpretation of the 2014 IMTG thymic epithelial tumor classification consensus [J]. Chin J Clin Exp Pathol, 31(2): 121-123.
Katsuya Yuki, Fujita Yu, Horinouchi Hidehito, Ohe Yuichiro, Watanabe Shun-Ichi, Tsuta Koji. 2015. Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma. Lung Cancer, 88, 154-9. https://doi.org/10.1016/j.lungcan.2015.03.003 DOI: https://doi.org/10.1016/j.lungcan.2015.03.003
Enkner Franz, Pichlhöfer Bettina, Zaharie Alexandru Teodor, Krunic Milica, Holper Tina Maria, Janik Stefan, Moser Bernhard, Schlangen Karin, Neudert Barbara, Walter Karin, Migschitz Brigitte, Müllauer Leonhard. 2017. Molecular Profiling of Thymoma and Thymic Carcinoma: Genetic Differences and Potential Novel Therapeutic Targets. Pathol. Oncol. Res, 23, 551-564. https://doi.org/10.1007/s12253-016-0144-8 DOI: https://doi.org/10.1007/s12253-016-0144-8
Tiseo Marcello, Damato Angela, Longo Lucia, Barbieri Fausto, Bertolini Federica, Stefani Alessandro, Migaldi Mario, Gnetti Letizia, Camisa Roberta, Bordi Paola, Buti Sebastiano, Rossi Giulio. 2017. Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs). Lung Cancer, 104, 24-30. https://doi.org/10.1016/j.lungcan.2016.12.005 DOI: https://doi.org/10.1016/j.lungcan.2016.12.005
Chen Yanmei, Zhang Yuping, Chai Xiaoling, Gao Jianfang, Chen Guorong, Zhang Weifen, Zhang Yunxiang. 2018. Correlation between the Expression of PD-L1 and Clinicopathological Features in Patients with Thymic Epithelial Tumors. Biomed Res Int, 2018, 5830547. https://doi.org/10.1155/2018/5830547 DOI: https://doi.org/10.1155/2018/5830547
Förster A, Grotha S P, Seeger J M, Rabenhorst A, Gehring M, Raap U, Létard S, Dubreuil P, Kashkar H, Walczak H, Roers A, Hartmann K. 2015. Activation of KIT modulates the function of tumor necrosis factor-related apoptosis-inducing ligand receptor (TRAIL-R) in mast cells. Allergy, 70, 764-74. https://doi.org/10.1111/all.12612 DOI: https://doi.org/10.1111/all.12612
Pan Chin-Chen, Chen Paul Chih-Hsueh, Chiang Hung. 2004. KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas. J. Pathol, 202, 375-81. https://doi.org/10.1002/path.1514 DOI: https://doi.org/10.1002/path.1514
Kim Bo-Sung, Kim Jin Kuk, Kang Chang Hyun, Kim Young Tae, Jung Kyeong Cheon, Won Jae-Kyung. 2018. An immunohistochemical panel consisting of EZH2, C-KIT, and CD205 is useful for distinguishing thymic squamous cell carcinoma from type B3 thymoma. Pathol. Res. Pract, 214, 343-349. https://doi.org/10.1016/j.prp.2018.01.009
Aydiner Adnan, Toker Alper, Sen Fatma, Bicakci Ercan, Saglam Esra Kaytan, Erus Suat, Eralp Yesim, Tas Faruk, Oral Ethem Nezih, Topuz Erkan, Dilege Sukru. 2012. Association of clinical and pathological variables with survival in thymoma. Med. Oncol, 29, 2221-8. https://doi.org/10.1007/s12032-011-0101-z DOI: https://doi.org/10.1007/s12032-011-0101-z
Schirosi L, Nannini N, Nicoli D, Cavazza A, Valli R, Buti S, Garagnani L, Sartori G, Calabrese F, Marchetti A, Buttitta F, Felicioni L, Migaldi M, Rea F, Di Chiara F, Mengoli M C, Rossi G. 2012. Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors. Ann. Oncol, 23, 2409-14. https://doi.org/10.1093/annonc/mdr626 DOI: https://doi.org/10.1093/annonc/mdr626
Giaccone Giuseppe, Rajan Arun, Ruijter Rita, Smit Egbert, van Groeningen Cees, Hogendoorn Pancras C W. 2009. Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas. J Thorac Oncol, 4, 1270-3. https://doi.org/10.1097/JTO.0b013e3181b6be57 DOI: https://doi.org/10.1097/JTO.0b013e3181b6be57
Palmieri Giovannella, Marino Mirella, Buonerba Carlo, Federico Piera, Conti Salvatore, Milella Michele, Petillo Luigi, Evoli Amelia, Lalle Maurizio, Ceribelli Anna, Merola Gerardina, Matano Elide, Sioletic Stefano, De Placido Sabino, Di Lorenzo Giuseppe, Damiano Vincenzo. 2012. Imatinib mesylate in thymic epithelial malignancies. Cancer Chemother. Pharmacol, 69, 309-15. https://doi.org/10.1007/s00280-011-1690-0 DOI: https://doi.org/10.1007/s00280-011-1690-0
Buti Sebastiano, Donini Maddalena, Sergio Pietro, Garagnani Lorella, Schirosi Laura, Passalacqua Rodolfo, Rossi Giulio. 2011. Impressive response with imatinib in a heavily pretreated patient with metastatic c-KIT mutated thymic carcinoma. J. Clin. Oncol, 29, e803-5. https://doi.org/10.1200/JCO.2011.36.6427 DOI: https://doi.org/10.1200/JCO.2011.36.6427
Girard Nicolas. 2010. Thymic tumors: relevant molecular data in the clinic. J Thorac Oncol, 5, S291-5. https://doi.org/10.1097/JTO.0b013e3181f209b9 DOI: https://doi.org/10.1097/JTO.0b013e3181f209b9
A. Kurup?M. Burns?S. Dropcho. 2005.Phase II study of gefitinib treatment in advanced thymic malignancies. J Clin Oncol, 23(16_suppl): 7068. https://doi.org/10.1200/jco.2005.23.16_suppl.7068 DOI: https://doi.org/10.1200/jco.2005.23.16_suppl.7068
Li Wenshan, Yu Qi, Li Ning. 2016. Expression and significance of EGFR and IGF-1R in thymoma. Chin J Clin Exp Pathol,32(3): 297-300.
Christodoulou C, Murray S, Dahabreh J, Petraki K, Nikolakopoulou A, Mavri A, Skarlos D. 2008. Response of malignant thymoma to erlotinib. Ann. Oncol, 19, 1361-2. https://doi.org/10.1093/annonc/mdn388 DOI: https://doi.org/10.1093/annonc/mdn388
Takahashi Eisuke, Koshiishi Haruya, Takahashi Masayoshi. 2011. [A response to erlotinib hydrochloride in the case of post-operative recurrent thymoma]. Gan To Kagaku Ryoho, 38, 2200-1.
Farina Gabriella, Garassino Marina C, Gambacorta Marcello, La Verde Nicla, Gherardi Giorgio, Scanni Alberto. 2007. Response of thymoma to cetuximab. Lancet Oncol, 8, 449-50. https://doi.org/10.1016/S1470-2045(07)70141-9 DOI: https://doi.org/10.1016/S1470-2045(07)70141-9
Steele Nicola L, Plumb Jane A, Vidal Laura, Tjørnelund Jette, Knoblauch Poul, Rasmussen Annie, Ooi Chean Eng, Buhl-Jensen Peter, Brown Robert, Evans T R Jeffry, DeBono Johann S. 2008. A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin. Cancer Res, 14, 804-10. https://doi.org/10.1158/1078-0432.CCR-07-1786 DOI: https://doi.org/10.1158/1078-0432.CCR-07-1786
Omatsu Mutsuko, Kunimura Toshiaki, Mikogami Tetsuya, Hamatani Shigeharu, Shiokawa Akira, Masunaga Atsuko, Kitami Akihiko, Suzuki Takashi, Kadokura Mitsutaka, Morohoshi Toshio. 2012. Immunohistochemical analysis of thymic carcinoma focusing on the possibility of molecular targeted and hormonal therapies. Gen Thorac Cardiovasc Surg, 60, 803-10. https://doi.org/10.1007/s11748-012-0160-x DOI: https://doi.org/10.1007/s11748-012-0160-x
Girard Nicolas, Teruya-Feldstein Julie, Payabyab Eden C, Riely Gregory J, Rusch Valerie W, Kris Mark G, Zakowski Maureen F. 2010. Insulin-like growth factor-1 receptor expression in thymic malignancies. J Thorac Oncol, 5, 1439-46. https://doi.org/10.1097/JTO.0b013e3181e392a8 DOI: https://doi.org/10.1097/JTO.0b013e3181e392a8
Haluska Paul, Shaw Heather M, Batzel Gretchen N, Yin Donghua, Molina Julian R, Molife L Rhoda, Yap Timothy A, Roberts M Luisa, Sharma Amarnath, Gualberto Antonio, Adjei Alex A, de Bono Johann S. 2007. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin. Cancer Res, 13, 5834-40. https://doi.org/10.1158/1078-0432.CCR-07-1118 DOI: https://doi.org/10.1158/1078-0432.CCR-07-1118
Giaccone Giuseppe, Rajan Arun, Berman Arlene, Kelly Ronan J, Szabo Eva, Lopez-Chavez Ariel, Trepel Jane, Lee Min-Jung, Cao Liang, Espinoza-Delgado Igor, Spittler John, Loehrer Patrick J. 2011. Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. J. Clin. Oncol, 29, 2052-9. https://doi.org/10.1200/JCO.2010.32.4467 DOI: https://doi.org/10.1200/JCO.2010.32.4467
A. Rajan, Arlene Berman, R. J. Kelly, Ariel Lopez-Chavez. 2010. Phase II study of the insulin-like growthfactor-1 receptor (IGF-1R) antibody cixutumumab (C) in patients (pts) with thymoma (T) and thymic carcinoma (TC) . J Clin Oncol, 28S: Abstract e17525. https://doi.org/10.1200/jco.2010.28.15_suppl.e17525 DOI: https://doi.org/10.1200/jco.2010.28.15_suppl.e17525
Cimpean Anca Maria, Raica Marius, Encica Svetlana, Cornea Remus, Bocan Viorica. 2008. Immunohistochemical expression of vascular endothelial growth factor A (VEGF), and its receptors (VEGFR1, 2) in normal and pathologic conditions of the human thymus. Ann. Anat, 190, 238-45. https://doi.org/10.1016/j.aanat.2007.05.003 DOI: https://doi.org/10.1016/j.aanat.2007.05.003
Tomita Masaki, Matsuzaki Yasunori, Edagawa Masao, Maeda Masayuki, Shimizu Tetsuya, Hara Masaki, Onitsuka Toshio. 2002. Correlation between tumor angiogenesis and invasiveness in thymic epithelial tumors. J. Thorac. Cardiovasc. Surg, 124, 493-8. https://doi.org/10.1067/mtc.2002.124389 DOI: https://doi.org/10.1067/mtc.2002.124389
Loehrer Patrick J, Wang Wei, Johnson David H, Aisner Seena C, Ettinger David S, Eastern Cooperative Oncology Group Phase II Trial. 2004. Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial. J. Clin. Oncol, 22, 293-9. https://doi.org/10.1200/JCO.2004.02.047 DOI: https://doi.org/10.1200/JCO.2004.02.047
Palmieri Giovannella, Buonerba Carlo, Federico Piera, Formisano Luigi, Nappi Lucia, Di Lorenzo Giuseppe, Marino Mirella, Damiano Vincenzo. 2012. Everolimus plus long-acting somatostatin analogs in thymic epithelial malignancies. World J Clin Oncol, 3, 111-5. https://doi.org/10.5306/wjco.v3.i7.111 DOI: https://doi.org/10.5306/wjco.v3.i7.111
Gbolahan Olumide B, Porter Ryan F, Salter John T, Yiannoutsos Constantin, Burns Matthew, Chiorean E Gabriella, Loehrer Patrick J. 2018. A Phase II Study of Pemetrexed in Patients with Recurrent Thymoma and Thymic Carcinoma. J Thorac Oncol, 13, 1940-1948. https://doi.org/10.1016/j.jtho.2018.07.094 DOI: https://doi.org/10.1016/j.jtho.2018.07.094
Gubens Matthew A, Burns Matthew, Perkins Susan M, Pedro-Salcedo Melanie San, Althouse Sandy K, Loehrer Patrick J, Wakelee Heather A. 2015. A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies. Lung Cancer, 89, 57-60. https://doi.org/10.1016/j.lungcan.2015.04.008 DOI: https://doi.org/10.1016/j.lungcan.2015.04.008
Chuah Charles, Lim Tse Hui, Lim Alvin Soon Tiong, Tien Sim Leng, Lim Chong Hee, Soong Richie, Lee Francis, Linn Yeh Ching, Goh Yeow Tee, Cheah Foong Koon, Loh Alwin Hwai Liang. 2006. Dasatinib induces a response in malignant thymoma. J. Clin. Oncol, 24, e56-8. https://doi.org/10.1200/JCO.2006.08.8963 DOI: https://doi.org/10.1200/JCO.2006.08.8963
Conforti Fabio, Wang Yisong, Rodriguez Jose A, Alberobello Anna Teresa, Zhang Yu-Wen, Giaccone Giuseppe. 2015. Molecular Pathways: Anticancer Activity by Inhibition of Nucleocytoplasmic Shuttling. Clin. Cancer Res, 21, 4508-13. https://doi.org/10.1158/1078-0432.CCR-15-0408 DOI: https://doi.org/10.1158/1078-0432.CCR-15-0408
Remon J, Abedallaa N, Taranchon-Clermont E, Bluthgen V, Lindsay C R, Besse B, Thomas de Montpréville V. 2017. CD52, CD22, CD26, EG5 and IGF-1R expression in thymic malignancies. Lung Cancer, 108, 168-172. https://doi.org/10.1016/j.lungcan.2017.03.019 DOI: https://doi.org/10.1016/j.lungcan.2017.03.019
Kiuchi Shizuka, Tomaru Utano, Ishizu Akihiro, Imagawa Makoto, Kiuchi Takayuki, Iwasaki Sari, Suzuki Akira, Otsuka Noriyuki, Deguchi Takahiro, Shimizu Tomohiro, Marukawa Katsuji, Matsuno Yoshihiro, Kasahara Masanori. 2017. Expression of cathepsins V and S in thymic epithelial tumors. Hum. Pathol, 60, 66-74. https://doi.org/10.1016/j.humpath.2016.09.027 DOI: https://doi.org/10.1016/j.humpath.2016.09.027
Petrini Iacopo, Meltzer Paul S, Kim In-Kyu, Lucchi Marco, Park Kang-Seo, Fontanini Gabriella, Gao James, Zucali Paolo A, Calabrese Fiorella, Favaretto Adolfo, Rea Federico, Rodriguez-Canales Jaime, Walker Robert L, Pineda Marbin, Zhu Yuelin J, Lau Christopher, Killian Keith J, Bilke Sven, Voeller Donna, Dakshanamurthy Sivanesan, Wang Yisong, Giaccone Giuseppe. 2014. A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors. Nat. Genet, 46, 844-9. https://doi.org/10.1038/ng.3016 DOI: https://doi.org/10.1038/ng.3016
Weissferdt Annikka, Moran Cesar A. 2011. Pax8 expression in thymic epithelial neoplasms: an immunohistochemical analysis. Am. J. Surg. Pathol, 35, 1305-10. https://doi.org/10.1097/PAS.0b013e3182260735 DOI: https://doi.org/10.1097/PAS.0b013e3182260735
Walts Ann E, Hiroshima Kenzo, Marchevsky Alberto M. 2015. Desmoglein 3 and p40 immunoreactivity in neoplastic and nonneoplastic thymus: a potential adjunct to help resolve selected diagnostic and staging problems. Ann Diagn Pathol, 19, 216-20. https://doi.org/10.1016/j.anndiagpath.2015.04.006 DOI: https://doi.org/10.1016/j.anndiagpath.2015.04.006
Li Songmei, Tan Wei, Huang Shubin, Hu Xiangyang. 2016. Expression and significance of ?5t, p63 and CD20 in Thymoma . Chin J Clin Exp Pathol, 32(3):292-296.
Leisibach Priska, Schneiter Didier, Soltermann Alex, Yamada Yoshi, Weder Walter, Jungraithmayr Wolfgang. 2016. Prognostic value of immunohistochemical markers in malignant thymic epithelial tumors. J Thorac Dis, 8, 2580-2591. https://doi.org/10.21037/jtd.2016.08.82 DOI: https://doi.org/10.21037/jtd.2016.08.82
Su Xue-Ying, Wang Wei-Ya, Li Jin-Nan, Liao Dian-Ying, Wu Wei-Lu, Li Gan-Di. 2015. Immunohistochemical differentiation between type B3 thymomas and thymic squamous cell carcinomas. Int J Clin Exp Pathol, 8, 5354-62.
Du Ms Jun, Shen Qin, Yin Honglin, Rao Qiu, Zhou Mr Xiaojun. 2016. Diagnostic roles of MUC1 and GLUT1 in differentiating thymic carcinoma from type B3 thymoma. Pathol. Res. Pract, 212, 1048-1051. https://doi.org/10.1016/j.prp.2016.09.005 DOI: https://doi.org/10.1016/j.prp.2016.09.005
Kim Bo-Sung, Kim Jin Kuk, Kang Chang Hyun, Kim Young Tae, Jung Kyeong Cheon, Won Jae-Kyung. 2018. An immunohistochemical panel consisting of EZH2, C-KIT, and CD205 is useful for distinguishing thymic squamous cell carcinoma from type B3 thymoma. Pathol. Res. Pract, 214, 343-349. https://doi.org/10.1016/j.prp.2018.01.009 DOI: https://doi.org/10.1016/j.prp.2018.01.009
Karube Yoko, Kobayashi Satoru, Maeda Sumiko, Sado Tetsu, Ishihama Hiromi, Chida Masayuki. 2016. Tumor-related gene expression levels in thymic carcinoma and Type B3 thymoma. J Cardiothorac Surg, 11, 85. https://doi.org/10.1186/s13019-016-0468-1 DOI: https://doi.org/10.1186/s13019-016-0468-1
Downloads
Published
How to Cite
Issue
Section
